| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Fair value change - earnout | - | - | -3,992 | - |
| Loss before tax | -72,005 | -17,364 | -39,527 | -16,648 |
| Loss for the period | -72,005 | -17,364 | -39,527 | - |
| Income tax expense (benefit) | - | - | - | -1 |
| Unrealized gain/(loss) on available-for-sale securities, net of tax | 313 | -107 | -33 | - |
| Total comprehensive loss for the period, net of tax | -71,692 | -17,471 | -39,560 | -16,647 |
| Earnings per share, basic | -0.61 | -0.15 | -0.34 | -0.18 |
| Earnings per share, diluted | -0.61 | -0.15 | -0.34 | -0.18 |
| Weighted average number of shares outstanding, basic | 119,000,266 | 118,556,492 | 116,124,941 | 94,754,140 |
| Weighted average number of shares outstanding, diluted | 119,000,266 | 118,556,492 | 116,124,941 | 94,754,140 |
NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS)